<DOC>
	<DOC>NCT00264875</DOC>
	<brief_summary>To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy</brief_summary>
	<brief_title>Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Participation in the preceding A0081066 doubleblind trial met the entry criteria for that trial and completed A0081066 study through visit 7 Experienced serious adverse event during the A0081066 trial that was considered related or possibly related to study medication by the investigator or sponsor noncompliant during A0081066 trial clinically significant or unstable medical condition both HIVrelated and nonHIV related including but not limited to, cardiac, pulmonary or hepatorenal disease that, in the opinion of the investigator, would compromise participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>